(S)-1-((S)-1-(((9H-Fluoren-9-Yl)Methoxy)Carbonyl)Pyrrolidine-2-Carbonyl)Pyrrolidine-2-Carboxylic Acid

Integration of consecutive proline residues via stepwise solid-phase peptide synthesis (SPPS) frequently results in elevated des-Pro and deletion sequences, particularly when resin loading exceeds 0.4 mmol/g and the growing chain adopts polyproline II helical conformations that restrict N-terminal accessibility. At production scale—exemplified by a 30 L cylindrical polypropylene reactor equipped with a bottom-filtered drainage manifold and an anchor impeller running at 45 rpm—failure to fully couple the second Pro residue manifests as a late-eluting impurity cluster in RP-HPLC (C18, 5 µm, 130 Å, linear gradient 5–25% MeCN over 20 min at 40 °C) that co-elutes within 0.6 min of the target product, necessitating costly dual-pass preparative chromatography. Substituting the consecutive amino acid additions with Fmoc-Pro-Pro-OH as a pre-formed dipeptide building block collapses that impurity profile: the crude purity of the linear precursor of a 12-residue Pro-rich GLP-1 analogue manufactured under these conditions rose from 72.4% to 89.1% (peak area, 214 nm) when 2.2 equivalents of the dipeptide activated with PyBOP (2.1 equiv) and N-methylmorpholine (4.5 equiv) in DMF at 0.35 M replaced sequential Fmoc-Pro-OH/DIC/Oxyma couplings. The dipeptide is dissolved at 0.30–0.45 M in anhydrous DMF (water content <100 ppm by Karl Fischer titration) and recycled through a 0.2 µm PTFE inline filter prior to delivery into the reaction vessel; coupling progress is tracked by Kaiser test turnover at 60 °C and, for GMP batches, by inline NIR monitoring of the resin-bound Fmoc chromophore at 304 nm. Scale-up campaigns operating under ICH Q7 for active pharmaceutical ingredients destined for metabolic disease indications additionally impose a requirement that any residual DMF in the isolated peptide be below 880 ppm in the final lyophilized cake, as verified by headspace GC-MS per USP <467>. The downstream process integrates cleavage with a TFA/triisopropylsilane/water (95:2.5:2.5 v/v) cocktail, precipitation in chilled methyl tert-butyl ether, and purification on a 15 cm ID C18 preparative column with a mobile phase of 0.1% TFA in water/acetonitrile to deliver the peptide API at >98.5% purity, which is then formulated by lyophilization into a sterile powder for injectable dosage forms. The finished therapeutic peptides incorporating the Pro-Pro motif span glucagon-like peptide-1 receptor agonists, melanocortin receptor ligands, and bradykinin B2 receptor antagonists, all of which require compliance with FDA 21 CFR 211 for finished pharmaceuticals and must demonstrate sequence fidelity by LC-MS/MS with mass accuracy better than 5 ppm.

Can a Single Dipeptide Block Reduce Deletion Impurities in Large-Scale Cyclic Peptide Manufacturing?

Cyclisation yields of head-to-tail lactam peptides containing a Pro-Pro sequence are sensitive to the geometry of the linear precursor, and the population of nonproductive trans conformers at the Pro1–Pro2 junction can exceed 65% in aqueous buffer at pH 7.4, as measured by ¹H-¹³C HSQC integration of Cα signals. When the linear peptide is assembled by sequential Fmoc-Pro-OH coupling on a 2-chlorotrityl chloride resin loaded at 0.65 mmol/g, the resulting epimerization at Pro2 Cα reaches 1.8–3.2% (D-Pro determined by Marfey’s test, LCI method) depending on the pre-activation time, directly reducing the isolated yield of the desired all-L cyclic monomer. Replacing the two consecutive Pro residues with the Fmoc-Pro-Pro-OH cassette at a coupling stoichiometry of 1.8 equivalents relative to free amino groups, using HATU (1.75 equiv) and 2,4,6-collidine (3.5 equiv) in a 1:1 v/v DMF/DCM mixture at 0 °C for 8 min, suppresses epimerization to below 0.3% and shifts the cis/trans ratio at the Pro1–Pro2 amide to roughly 45:55, a distribution that facilitates subsequent macrolactamization. Industrial production—performed in a 50 cm × 12 cm ID glass column reactor with a circulating jacket at 23 ± 1 °C and nitrogen ebullition for solvent infiltration—adheres to ICH Q11 development standards for starting materials and ICH Q7 for active pharmaceutical ingredient manufacture. The cyclisation step, executed by dropwise addition of the purified linear precursor (1.0 mM in DMF) into a stirred solution of PyBOP (3 equiv) and DIEA (6 equiv) at 50 °C over 4 h, consistently yields chromatographic purities of the crude cyclic product exceeding 79% when the Pro-Pro dipeptide strategy is used, in contrast to 51–58% for the traditional two-step method. Purification by reversed-phase flash chromatography with a target loading of 12 g/L of stationary phase and lyophilisation from 0.1 M acetic acid produces the acetate salt of the cyclic peptide, used as a standard in antimicrobial susceptibility testing and as a reference material for peptide mass spectrometry. Terminal products include polymyxin-inspired cyclic heptapeptides, β-hairpin antibiotic candidates, and macrocyclic integrin-binding antagonists, all catalogued under ISO 13485 if intended as components of medical device coating materials or as analytical reference standards traceable to USP <1045>.

Incorporation of Fmoc-Pro-Pro-OH into the synthesis of repetitive collagen-model peptides of formula (Gly-Pro-Pro)_n where n = 5–10 addresses the kinetic barrier imposed by the slow cis-to-trans isomerisation of Xaa-Pro bonds during chain assembly on low-loading PEG-based resins. At a synthesis scale of 15 mmol on ChemMatrix resin (loading 0.25 mmol/g) inside a 20 cm × 8 cm sintered-glass reactor, stepwise addition of single Pro units requires average coupling times of 90 min at 50 °C with DIC/Oxyma and is frequently interrupted by resin shrinkage exceeding 8% linear contraction in DMF, leading to channeling and incomplete deprotection. By deploying the Fmoc-Pro-Pro dipeptide at a molar excess of 2.0–2.3 equiv with PyBOP activation and an uninterrupted reaction time of 45 min at 35 °C, the assembly of a 24-residue (Gly-Pro-Pro)₈ sequence is completed in two synthetic days rather than four, with the crucial advantage that the ratio of full-length peptide to (n-1) truncation products improves from 6.2:1 to 18.4:1 as determined by LC-MS extracted ion chromatograms. The composition of the dipeptide stock solution is adjusted to 0.38 M in DMF with 0.05 M LiBr added to disrupt peptide-chain aggregation through chaotropic action, a measure specifically effective for collagen-like tripeptide repeats. Downstream, the purified peptide is dissolved to 0.8 mM in 10 mM sodium phosphate buffer, pH 7.0, and the triple-helix folding is monitored by temperature-dependent circular dichroism at 222 nm using a 1 mm path-length cell; the thermal transition midpoint (T_m) of 58.5 °C correlates with triple-helical content that must remain above 85% at 37 °C for the material to serve as a scaffold in regenerative templates. Regulatory oversight of such scaffolds invokes ISO 10993-1:2018 for biological evaluation of medical devices and ISO 13485:2016 for quality management, with endotoxin limits set at <0.5 EU/mg per USP <85>. The terminal products range from lyophilized collagen-mimetic peptides used as tissue-engineering hydrogel components to chemically cross-linked fibrous mats produced via electrospinning from 30% (w/v) peptide solutions in hexafluoroisopropanol, utilized in corneal wound healing patches and guided bone regeneration membranes.

When a Proline-Rich Antimicrobial Sequence Demands a Pre-assembled Dipeptide

Proline-rich antimicrobial peptides (PrAMPs), such as the insect-derived apidaecins and mammalian Bac7 fragments, require contiguous Pro-Pro sequences that are essential for their non-lytic internalization and subsequent inhibition of bacterial DnaK chaperone activity. During solid-phase assembly of an apidaecin Ib analogue on a 10 mmol scale using a TentaGel S RAM resin (0.22 mmol/g), the sequential coupling of the central Pro-Pro motif with Fmoc-Pro-OH/(HBTU/DIEA) at 25 °C gave rise to a +98 Da side-product identified by high-resolution mass spectrometry as Nα-acetyl Pro, a fragmentation product tracing back to premature Fmoc loss during extended activation. Switching to Fmoc-Pro-Pro-OH as a cassette removed the acetyl impurity entirely, with the activated ester of the dipeptide proving sufficiently stable to act at a coupling stoichiometry of 2.0 equiv for 30 min at 45 °C without detectable loss of the Fmoc group. The manufacturing protocol, conducted under an ICH Q7-aligned quality system, specifies dissolution of the dipeptide in a 1:1 mixture of DMF and NMP (v/v) containing 0.8 M Oxyma Pure and 1.8 M DIC, with the solution held at 4–8 °C for no longer than 6 h before use. Post-assembly, the peptide is cleaved with a TFA/ethanedithiol/thioanisole/anisole (92:4:2:2) mixture, precipitated in diethyl ether, and purified through a combination of cation-exchange chromatography (SP Sepharose FF, elution with 0.3 M NaCl in 20 mM acetate, pH 5.0) and C18 preparative HPLC to reach final purity above 98.0%. The purified antimicrobial peptide, formulated as an acetate salt, is intended for parenteral administration and thus must meet FDA 21 CFR 312 guidelines for investigational new drugs, including a minimum inhibitory concentration (MIC) determination against Escherichia coli ATCC 25922 of <8 µg/mL and a hemolytic activity <1% at 256 µg/mL measured on fresh human erythrocytes. In commercial synthesis settings, the Fmoc-Pro-Pro building block minimizes batch-to-batch peptide content variance by more than 4% relative to stepwise assembly, a critical advantage when the active pharmaceutical ingredient is incorporated into a liposomal suspension or a polymeric nanoparticle matrix for inhalation delivery in cystic fibrosis patients.

Construction of peptide-drug conjugates (PDCs) demands linker sequences that remain stable in systemic circulation yet release the cytotoxic payload with high selectivity upon uptake by tumour cells. The Pro-Pro dipeptide, when placed as the penultimate motif adjacent to a lysine-linked cathepsin B-sensitive Val-Cit sequence, creates a substrate for the serine protease fibroblast activation protein (FAP), which is overexpressed in the tumour stroma of epithelial cancers. A representative linker module assembled on a 0.15 mmol scale on Rink amide resin inside a standard 25 mL SPPS syringe fitted with a porous polyethylene disc bound the Fmoc-Pro-Pro fragment at 2.5 equiv using COMU (2.4 equiv) and 2,4,6-trimethylpyridine (5 equiv) in DMF at 20 °C for 25 min, yielding a homogeneous intermediate that after full chain elongation and cleavage delivered the linker-derivatized peptide with an isolated yield of 76%. Process controls at this stage include an in-process identity test by MALDI-TOF MS on a 1 µL aliquot of resin beads after TFA microcleavage, with an observed m/z within ±0.8 Da of the theoretical monoisotopic mass. The complete PDC is prepared later by conjugation of the purified linker-bearing peptide with a maytansinoid derivative through a pH 7.2 phosphate-buffered maleimide-thiol reaction, desalted over a Sephadex G-25 column, and subjected to hydrophobic interaction chromatography for drug-to-antibody ratio assessment. Compliance with ICH M3(R2) nonclinical safety pharmacology and ICH Q6B specifications for biotechnological products is mandatory for Phase I studies; the linker fragment must be characterized by amino acid analysis showing a Pro recovery of 1.95–2.10 mol/mol and by residual tin analysis (if stannous-assisted reductions are used) at <10 µg/g. The finished conjugate, formulated as a lyophilized powder for infusion containing 5 mg/mL of the conjugate upon reconstitution, falls into the class of antineoplastic agents exemplified by solid-tumour-targeted PDCs currently undergoing clinical evaluation for pancreatic ductal adenocarcinoma and platinum-resistant ovarian cancer.

Where Fmoc-Pro-Pro Facilitates MHC-II Epitope Presentation in Synthetic Peptide Vaccines

Tumour neoantigen vaccines frequently embed a Pro-Pro sequence within the 15–25 amino acid epitope to constrain the backbone into a type I β-turn that enhances binding to the MHC-II cleft, an effect documented for the NY-ESO-1 peptide _87–111 analogues in which Pro residues at positions i and i+1 stabilize the P4/P5 pockets. The industrial manufacture of such long peptides on a Wang resin pre-loaded with Fmoc-Gly-OH (0.42 mmol/g) calls for introduction of the Fmoc-Pro-Pro segment via a 2.0 equivalent charge dissolved in a 1:2 v/v mixture of DMSO and NMP to penetrate the resin matrix effectively; activation is carried out with HATU (1.95 equiv) and 2,4,6-trimethylpyridine (4 equiv) at 37 °C for 18 min. Following final TFA cleavage, the crude peptide is purified by tandem preparative HPLC (first dimension pH 2.0 TFA system, second dimension pH 9.0 ammonium bicarbonate mobile phase) to obtain the trifluoroacetate-free product, a prerequisite for GMP vaccine formulations because counter-ion removal prevents injection-site inflammation and ensures compliance with WHO TRS 978 for synthetic peptide vaccines. An ELISA-based potency assay using serum from HLA-DRB1*0401-transgenic mice quantifies the EC₅₀ of the final peptide at <0.5 nM, verifying that the Pro-Pro turn is preserved post-formulation. The lyophilized multi-epitope peptide cocktail, containing 250 µg per vial of each component along with a poly-ICLC adjuvant, is reconstituted in sterile water and administered subcutaneously. While the dipeptide building block itself accounts for only 7–10% of the total amino acid input by mole fraction, its contribution to the correct conformational presentation and batch-to-batch immunological reproducibility is disproportionate, reducing the CV of T-cell ELISpot responses from 23% to 9% across three consecutive production lots conducted under ICH Q7 and 21 CFR 610 general biological product standards.